Wednesday, November 11, 2026

AI-native vendors close record enterprise deals as legacy software loses ground

Purpose-built AI platforms are winning enterprise contracts over traditional software providers, driven by integrated capabilities legacy systems can't match. SoundHound AI reported record customer deals in Q4 2025, while Baidu's AI cloud revenue hit CNY 30 billion. The shift reflects enterprises prioritizing native AI infrastructure over retrofitted solutions.

AI-native vendors close record enterprise deals as legacy software loses ground
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

AI-native vendors closed a record number of enterprise deals in late 2025, capturing market share from traditional software providers struggling to retrofit AI capabilities into legacy systems.

SoundHound AI CEO Keyvan Mohajer reported record customer deals in Q4 2025, with all key profit metrics rising. "As traditional software faces massive AI disruption, businesses are looking to partner with AI natives," Mohajer said.

Baidu's AI cloud business—combining infrastructure and applications—reached CNY 30 billion ($4.1 billion) in revenue, demonstrating enterprise appetite for integrated AI platforms. The company's bundled approach contrasts with traditional cloud vendors adding AI as separate services.

Rezolve AI noted most legacy digital experience platforms lack native AI, conversational interfaces, or transaction-capable agents. The company positioned itself among the few combining proprietary LLMs with deep platform integration—a capability enterprises now prioritize in vendor selection.

The vendor consolidation stems from enterprises avoiding technical debt. Legacy systems require expensive middleware to connect AI features, creating performance bottlenecks and security gaps. Purpose-built platforms eliminate these layers.

Three factors drive the shift. First, AI-native vendors design data pipelines, model serving, and application layers as unified systems rather than bolted-on modules. Second, they optimize hardware and software together, improving inference speed and cost efficiency. Third, their development cycles move faster than enterprise IT departments can upgrade legacy stacks.

Traditional software vendors face a catch-22: rushing AI features risks quality, but slow rollouts lose customers to AI-first competitors. Many enterprises now specify "native AI architecture" in RFPs, effectively disqualifying retrofitted solutions.

The procurement shift appears across industries. Financial services, healthcare, and manufacturing buyers increasingly favor vendors who built AI capabilities from inception rather than acquisition. This preference shows in contract values—AI-native platforms command premium pricing while legacy vendors discount to retain accounts.

Analyst estimates suggest AI-native vendors captured 40-45% of new enterprise AI platform deals in H2 2025, up from 25% a year earlier. If the trend continues, traditional software companies may need acquisitions or complete platform rebuilds to remain competitive in AI-dependent enterprise workflows.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com